Our Pipeline

About GDD3898

GDD3898 is a clinical-stage Phase 2 drug candidate being developed by Lipidio Pharmaceuticals. Lipidio plans to leverage existing efficacy and human safety data for GDD3898 and conduct new clinical studies to strengthen support for its therapeutic potential in multiple indications.

Sebaceous
Hyperplasia Phase 2 Phase 1B Phase 1 Non-Clinical GDD3898 Obesity
Obesity GDD3898 Phase 2 Phase 1B Phase 1 Non-Clinical Sebaceous
Hyperplasia